Compositions and methods for detecting pancreatic cancer
AssigneeThe Johns Hopkins University
InventorsJin Song, Zhen Zhang, Daniel Wan-yui Chan
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject a level of CA19-9 polysaccharide relative to a reference, and a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of: OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference, wherein an increased level of the CA19-9 polysaccharide relative to a reference and an increased level of the polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.
Claims14
A method of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject
- a level of CA19-9 polysaccharide relative to a reference, and
- a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of:
- OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference,
- wherein an increased level of said CA19-9 polysaccharide relative to a reference and an increased level of said polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.
A method of distinguishing a pancreatic ductal adenocarcinoma (PDAC) from a benign pancreatic condition, the method comprising measuring in a sample from the subject
- a level of CA19-9 polysaccharide relative to a reference, and
- a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of:
- OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference.
A method of selecting a subject for pancreatic cancer treatment, the method comprising detecting in a sample from the subject
- an increased level of CA19-9 polysaccharide relative to a reference, and
- an increased level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of:
- OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference.
(canceled)
8-13. (canceled)
(canceled)
19-28. (canceled)
Dependencies are inferred from the claim text.